1960-52-7

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYL-4-NITROBENZOTRIFLUORIDE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-METHYL-4-NITROBENZOTRIFLUORIDE is utilized as an intermediate in the production of pesticides and other agricultural chemicals. Its properties contribute to the effectiveness and performance of these products in protecting crops and enhancing agricultural yields.
Used in Dye Industry:
2-METHYL-4-NITROBENZOTRIFLUORIDE is employed as a key intermediate in the manufacturing of dyes. Its chemical properties allow for the creation of a wide range of colors and hues, making it an essential component in the dye industry.
Safety and Environmental Considerations:
Due to its flammable nature and potential health risks, 2-METHYL-4-NITROBENZOTRIFLUORIDE should be handled with caution. It is essential to store it in a cool, dry place away from heat and open flames, and to keep it out of reach of children and pets. Additionally, its use and disposal must adhere to all applicable laws and regulations to minimize environmental impact and health risks.

InChI:InChI=1/C8H6F3NO2/c1-5-4-6(12(13)14)2-3-7(5)8(9,10)11/h2-4H,1H3

Upstream product

• 2314-97-8 iodotrifluoromethane 
• 5326-38-5 2-iodo-5-nitrotoluene 
• 2923-16-2 potassium trifluoroacetate 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 680-15-9 2,2-difluoro-2-(fluorosulfonyl)acetate 

Downstream Products

• 930599-57-8 4-iodo-2-methyl-1-(trifluoromethyl)benzene 
• 1261682-47-6 2-(bromomethyl)-4-iodo-1-(trifluoromethyl)benzene 
• 1445983-30-1 (4-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)(1-(5-iodo-2-(trifluoromethyl)benzylamino)cyclopropyl)methanone 
• 1445985-71-6 methyl 5-(3-((1-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)cyclopropylamino)methyl)-4-(trifluoromethyl)phenyl)pent-4-ynoate 
• 1445985-72-7 methyl 5-(3-((1-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)cyclopropylamino)methyl)-4-(trifluoromethyl)phenyl)pentanoate 
• 1445985-73-8 5-(3-((1-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)cyclopropylamino)methyl)-4-(trifluoromethyl)phenyl)pentanoic acid 
• 1445983-45-8 5-(3-((1-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)cyclopropylamino)methyl)-4-(trifluoromethyl)phenyl)-N-methyl-N-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)pentanamide 
• 1610862-24-2 C₃₃H₃₄Cl₂F₅N₃O₈S 
• 1610862-27-5 benzyl 5-(N-(2-morpholinoethyl)methylsulfonamido)-2-(trifluoromethyl)benzoate 
• 1610862-26-4 5-(N-(2-morpholinoethyl)methylsulfonamido)-2-(trifluoromethyl)benzoic acid 
• 1609677-84-0 3-(4-ethyl-piperazin-1-ylmethyl)-4-trifluoromethyl-phenylamine 
• 1609677-83-9 (5-amino-2-trifluoromethyl-phenyl)-(4-ethyl-piperazin-1-yl)-methanone 
• 1609677-81-7 (4-ethyl-piperazin-1-yl)-(5-nitro-2-trifluoromethyl-phenyl)-methanone 
• 1610862-28-6 benzyl 5-(methylsulfonamido)-2-(trifluoromethyl)benzoate 

Relevant academic research and scientific papers

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series

Acylaminobenzothiazole hits were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic stability (human clearance = 9.57 mL/min/g). A total of 39 analogues of 1 were synthesized and tested in vitro. We established a multiparametric structure-activity relationship, allowing optimization of antiparasite activity, physicochemical parameters, and ADME properties. We identified compound 50 as an advanced lead with an improved anti-T. cruzi activity in vitro (IC50 = 0.079 μM) and an enhanced metabolic stability (human clearance = 0.41 mL/min/g) and opportunity for the oral route of administration. After tolerability assessment, 50 demonstrated a promising in vivo efficacy.

Conversion of aromatic amino into trifluoromethyl groups through a Sandmeyer-type transformation

A novel strategy for aromatic trifluoromethylation by converting amino into trifluoromethyl groups via a Sandmeyer-type reaction is reported. The transformation involves diazotization of the aromatic amines with tert-butyl nitrite and hydrochloric acid to form aryldiazonium chlorides, followed by trifluoromethylation with trifluoromethylsilver at low temperature. Various readily available aromatic amines are smoothly converted under mild conditions. Georg Thieme Verlag Stuttgart. New York.

Rapid and efficient trifluoromethylation of aromatic and heteroaromatic compounds using potassium trifluoroacetate enabled by a flow system

Going to the source: The trifluoromethylation of aryl/heteroaryl iodides has been demonstrated using a flow system, thus enabling a rapid rate of reaction. A broad spectrum of trifluoromethylated compounds was prepared in good to excellent yields using CF3CO2K as the trifluoromethyl source. The process has the advantage of short reaction times and uses convenient [CF3] sources. Copyright

Silver-mediated trifluoromethylation of aryldiazonium salts: Conversion of amino group into trifluoromethyl group

A novel strategy for aromatic trifluoromethylation by converting aromatic amino group into CF3 group is reported herein. This method, which can be considered as trifluoromethylation variation of the classic Sandmeyer reaction, uses readily available aromatic amines as starting materials and is performed under mild conditions.

NON-SYSTEMIC TGR5 AGONISTS

Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl- 3-hydroxy. N-[3'-methyl-4'-(trifluoromethyl)phenyl]propenamide and related compounds

The active metabolite (2) of the novel immunosuppressive agent leflunomide (1) has been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme catalyzes the fourth step in de novo pyrimidine biosynthesis. A series of analogues of the active metabolite 2 have been synthesized. Their in vivo biological activity determined in rat and mouse delayed type hypersensitivity has been found to correlate well with their in vitro DHODH potency. The most promising compound (3) has shown activity in rat and mouse collagen (II)-induced arthritis models (ED50 = 2 and 31 mg/kg, respectively) and has shown a shorter half-life in man when compared with leflunomide. Clinical studies in rheumatoid arthritis are in progress.